Device Firm Earnings: Winners And Losers
This article was originally published in The Gray Sheet
Executive Summary
In this earnings review, we pick out the high achievers and underperformers from the companies that released quarterly results in the past week. Reports from J&J, ResMed, bioMérieux, St. Jude Medical and more.
You may also be interested in...
In Case You Missed It: Top 10 Gray Sheet Stories In February
Our coverage of the highly anticipated release of the revised ISO 13485 international medical device quality systems standard attracted the most attention from Gray Sheet readers last month. Also popular: stories about FDA photography during facility inspections, European postmarket surveillance reforms, and policy updates focused on human factors.
Cardinal Health Builds On Generic Device Strategy With Cordis Deal
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”